Advanced cancer patients per year in the United States without an actionable driver
%
Driver-negative patients have alterations in a gene targeted by an FDA-approved therapy
Driver-negative solid tumor patients in the Aventa clinical study
Aventa FusionPlus

What

How

Why

Reveal druggable targets
Fusions in genes like ALK, ROS, RET, and NTRK are targeted by fusion-inhibiting therapies. The Aventa FusionPlus test doubles the diagnostic yield of these targetable fusions, providing better treatment options for these patients.

Resolve diagnostic dilemmas
Translocations are the basis for definitive diagnosis in sarcomas, salivary gland cancers, brain cancers, and others. The Aventa FusionPlus test identifies translocations in the genes most commonly used for tumor diagnosis.
361 Genes in the Aventa FusionPlus Test

Aventa Assist
Aventa is committed to ensuring access for all eligible patients. If insurance approves test coverage, patients are only responsible for their copay, coinsurance, and deductible. Their out-of-pocket cost may be further reduced if they are eligible for financial assistance through the Aventa Assist program. Please contact us if you have any questions.
